You are here: Industry Insights > Novartis

News List

Novartis, Mundipharma to enhance access of ophthalmology drugs biospectrumasia
July 28, 2019
To market, sell and distribute Novartis medicines in the general ophthalmology disease area
Gilead gets licences to three antiviral programmes from Novartis pharmaceutical-technology
July 23, 2019
Gilead Sciences has secured an antiviral deal with Novartis to gain exclusive global rights to preclinical programmes involving candidates for the treatment of various viral infections.
UK’s NICE backs Novartis breast cancer drug Kisqali pharmaceutical-technology
July 22, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has approved Novartis’ drug Kisqali (ribociclib) in combination with fulvestrant for the treatment of certain patients with advanced breast cancer.
Novartis' key multiple sclerosis product Gilenya gets approval in China biospectrumasia
July 20, 2019
Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older
Novartis, aiming to clean up its rep, sets aside $700M for kickback settlement fiercepharma
July 20, 2019
With nearly decade-old bribery charges hanging over its head, Novartis has been eager to wriggle out of U.S. prosecutors’ crosshairs. Now, a settlement in the case appears to be in the works—and it could cost Novartis close to a billion dollars.
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO fiercepharma
July 20, 2019
Gene therapy Zolgensma is under the spotlight as Novartis launches what’s known as the world’s most expensive drug. And now, its chief has offered an early glimpse into the rollout.
Novartis continues to build healthcare talent ecosystem, announces BioCamp 2019 expresspharma
July 18, 2019
The next edition of Novartis Biotechnology Leadership Camp (BioCamp) will be taking place in Hyderabad from October 13 to 16, 2019. Now in its 11th year, BioCamp has attracted top talent from across faculties to the healthcare industry thus contributing t
Amgen and Novartis discontinue Alzheimer’s drug development programme pharmaceutical-technology
July 17, 2019
Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s disease, which the Arizona-based Banner Alzheimer’s Institute was also supporting.
Recordati acquires rights to Signifor and osilodrostat from Novartis pharmaceutical-technology
July 17, 2019
Recordati has agreed to acquire the global rights to two of Novartis’ medicines, Signifor and osilodrostat, for the treatment of patients suffering from endocrine diseases.
FDA Accepts BLA, Grants Priority Review for Crizanlizumab americanpharmaceuticalreview
July 17, 2019
Novartis announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle cell medicine crizanlizumab (SEG101).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page